Vertex Pharmaceuticals (VRTX)

CrowdStrike has expanded its partnership with Google Cloud to enable end-to-end security for AI innovation.

A group of S&P 500 stocks have remained resilient as tariffs and earnings concerns cause the market to drop. Future gains may be limited.

Vertex Pharmaceuticals sees early success with Journavx painkiller, potential revenue growth from drug and gene therapy.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at therapeutics stocks, starting with United Therapeutics (NASDAQ:UTHR).

Trump's new tariff move may raise U.S. pharma costs, with analysts warning of risks tied to EU manufacturing and shifting healthcare policies.

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q4, starting with Amgen (NASDAQ:AMGN).

The sector's recent slide follows Peter Marks' resignation last week as the Food and Drug Administration's top vaccine regulator following a clash with Kennedy.

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe type 1 diabetes, toward approval.

Exploring VERTEX PHARMACEUTICALS INC's Technical Signals and Breakout Potential: Based on good technical signals, VERTEX PHARMACEUTICALS INC is potentially setting up for a breakout.

The FDA is due to make an approval decision in mid-September for a key product from the top pharma company.

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season.

Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season.